BioPharma Dive 2025-11-26 Novartis cuts hundreds of jobs; Novo’s dual-acting diabetes drug heading to Phase 3
BioPharma Dive 2025-11-26 Otsuka gains approval for first-of-its-kind treatment against rare kidney disease